ERBB2 and triple-negative breast carcinoma: In addition, patients with hormone receptor (HR)+/HER2+ breast cancer with LM have a longer median survival than patients with HR+/HER2- and triple-negative breast cancer due to the introduction of HER2-targeted therapy [17,18].